Deep research
About NAD+ Peptide Complex
NAD+ (nicotinamide adenine dinucleotide) is a dinucleotide coenzyme with a molecular weight of 663.43 Da, composed of two nucleotides joined through their phosphate groups: one containing an adenine base, the other containing nicotinamide. It exists in oxidized (NAD+) and reduced (NADH) forms, serving as the primary electron carrier in over 500 enzymatic reactions across every cell in the body. NAD+ is the important substrate for three major enzyme families: sirtuins (SIRT1-7), poly(ADP-ribose) polymerases (PARPs), and CD38/CD157 ectoenzymes.
NAD+ levels decline by approximately 50% between ages 40 and 60, as measured by Zhu et al. (2015) in human tissue samples. This decline results from increased consumption by CD38 (which rises with chronic inflammation), decreased synthesis via the NAMPT salvage pathway, and accumulated DNA damage driving PARP activation. The NAD+ decline is now recognized as a central node connecting multiple hallmarks of aging, including mitochondrial dysfunction, genomic instability, and cellular senescence.
The sirtuin family of NAD+-dependent deacetylases has received particular attention in longevity research. SIRT1 activation improves insulin sensitivity, promotes mitochondrial biogenesis via PGC-1alpha, and enhances autophagy. SIRT3 protects mitochondrial function directly. SIRT6 maintains telomere integrity and DNA repair. All seven sirtuins require NAD+ as a co-substrate, making NAD+ availability a rate-limiting factor for their activity. David Sinclair's lab at Harvard demonstrated that NAD+ restoration via NMN supplementation reversed age-related muscle degeneration and improved mitochondrial function in aged mice (Gomes et al., Cell, 2013).
Our NAD+ Peptide Complex is designed to support endogenous NAD+ biosynthesis through multiple precursor pathways. The salvage pathway, which recycles nicotinamide back to NAD+ via the enzyme NAMPT, accounts for approximately 85% of cellular NAD+ production. By supplying both direct precursors and peptides that upregulate NAMPT expression, this formula addresses the decline from the most physiologically relevant angle.
Preclinical research from Washington University (Yoshino et al., Cell Metabolism, 2011) showed that NAD+ precursor administration restored glucose tolerance in aged and diet-induced diabetic mice. Subsequent work demonstrated improved cardiac function, enhanced neuronal survival under stress, and a 5% extension of healthy lifespan in mouse models. Human clinical trials with NAD+ precursors (METRO trial, N=120) showed increased whole-blood NAD+ levels by 40-90% with good tolerability.
NAD+ itself has poor oral bioavailability due to rapid degradation in the gastrointestinal tract. Parenteral administration (subcutaneous or intravenous) provides direct systemic availability. IV NAD+ infusions are typically administered over 2-4 hours due to potential flushing and nausea with rapid infusion. Subcutaneous peptide complex formulations offer a more practical alternative for research protocols, with dosing typically ranging from 50-200 mg per administration.
Lyophilized NAD+ complex should be stored at -20C and is stable for 18+ months. Reconstituted solution should be refrigerated at 2-8C, protected from light, and used within 28 days. NAD+ is light-sensitive and will degrade under UV exposure. The solution should remain clear and colorless; any yellowing indicates degradation. pH stability range is 6.5-7.5.
The safety profile of NAD+ supplementation is well-characterized. The most commonly reported effects with parenteral administration are transient flushing, mild nausea, and chest tightness during rapid IV infusion, all of which resolve by slowing infusion rate. Long-term oral precursor studies (up to 12 months) have shown no hepatotoxicity, nephrotoxicity, or other organ-specific adverse effects. NAD+ is an endogenous molecule present in every living cell, which provides an inherent safety baseline.
